Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic‐Experienced Patients With Ulcerative Colitis: A Retrospective Study
Journal of Digestive Diseases · 2025-09 · 26 (9-10) · 428-435
DOI: 10.1111/1751-2980.70012 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Digestive Diseases, online erschienen am 09.10.2025. Verfasst von Neta Sror und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine B, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal, Humanized, Heterocyclic Compounds, 3-Ring, Gastrointestinal Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Upadacitinib (UPA) and vedolizumab (VDZ) have been approved to treat moderate‐to‐severe ulcerative colitis (UC); however, direct comparative data between these two regimens are lacking. We aimed to compare the effectiveness and safety of UPA and VDZ among patients with moderate‐to‐severe UC who had previously been treated with advanced therapies.
Methods
Patients with moderate‐to‐severe UC receiving VDZ or UPA for at least 14 weeks following advanced therapy failure, including at least one anti‐tumor necrosis factor (TNF) agent, between 2015 and 2024, were retrospectively recruited. Clinical response and remission were defined by the Partial Mayo Score and the Simple Clinical Colitis Activity Index. The safety profile during the treatment was also compared.
Results
Altogether 66 patients treated with VDZ and 22 patients with UPA were included. The median age of the VDZ and UPA groups was 38 and 37 years, respectively. Patients receiving UPA achieved significantly higher rates of corticosteroid‐free remission after 52‐week therapy (75.0% vs. 25.0%; adjusted odds ratio [aOR] 5.68, 95% confidence interval [CI] 1.50–21.00, p = 0.011); however, these patients were more likely to experience adverse events (AEs) (40.9% vs. 9.1%; aOR 4.60, 95% CI 1.20–17.00, p = 0.02), although medication discontinuation due to AEs was only noted in two (3.0%) patients receiving VDZ. No patients were hospitalized during the treatment period.
Conclusion
UC patients receiving UPA achieved significantly higher rates of corticosteroid‐free clinical remission but with more AEs, suggesting that decision‐making based on disease severity and comorbidities can help guide the positioning of these therapies in UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine B, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel.
- Affiliated With the Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
ORCID-Profile: Neta Sror, Haim Leibovitzh
Zitieren
APA
Sror, N., Leibovitzh, H., Hirsch, A., Thurm, T., Ron, Y., Maharshak, N., & Cohen, N. A. (2025). Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic‐Experienced Patients With Ulcerative Colitis: A Retrospective Study. Journal of Digestive Diseases, 26(9-10), 428-435. https://doi.org/10.1111/1751-2980.70012
Vancouver
Sror N, Leibovitzh H, Hirsch A, Thurm T, Ron Y, Maharshak N, et al. Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic‐Experienced Patients With Ulcerative Colitis: A Retrospective Study. Journal of Digestive Diseases. 2025;26(9-10):428-435. doi:10.1111/1751-2980.70012
BibTeX
@article{Sror2025,
author = {Sror, Neta and Leibovitzh, Haim and Hirsch, Ayal and Thurm, Tamar and Ron, Yulia and Maharshak, Nitsan and Cohen, Nathaniel Aviv},
title = {Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic‐Experienced Patients With Ulcerative Colitis: A Retrospective Study},
journal = {Journal of Digestive Diseases},
year = {2025},
volume = {26},
number = {9-10},
pages = {428--435},
doi = {10.1111/1751-2980.70012}
}
EUVIMED